Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
Summit Therapeutics (SMMT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
● Zacks Investment ResearchNov 16, 2026 · 13:15 ETEARNINGS EXPECTED BY FEB 22
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.…
Two cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major clinical and regulatory dev…
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BL…
● Zacks Investment ResearchNov 10, 2026 · 10:56 ETEARNINGS EXPECTED BY FEB 22
Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 62.3% in Summit Therapeutics (SMMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend…
● Business WireNov 4, 2026 · 16:36 ETEARNINGS EXPECTED BY FEB 22
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operat…
● Business WireOct 25, 2026 · 11:52 ETEARNINGS EXPECTED BY FEB 22
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-c…
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (K…
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered p…
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), tak…
● Zacks Investment ResearchOct 21, 2026 · 12:01 ET
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.…
● PRNewsWireOct 21, 2026 · 08:42 ETEARNINGS EXPECTED BY FEB 22
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.…
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential …
● Business WireOct 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class inves…
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support contin…
Article counts from the last market-wide feed page, across every symbol we track and not just SMMT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.